[go: nahoru, domu]
Jump to content

CYP3A4

From Wikipedia, the free encyclopedia

CYP3A4
Identifiers
EC no.1.14.14.56
Databases
IntEnzIntEnz view
BRENDABRENDA entry
ExPASyNiceZyme view
KEGGKEGG entry
MetaCycmetabolic pathway
PRIAMprofile
PDB structuresRCSB PDB PDBe PDBsum
Search
PMCarticles
PubMedarticles
NCBIproteins
CYP3A4
Available structures
PDBHuman UniProt search: PDBe RCSB
Identifiers
AliasesCYP3A4, CP33, CP34, CYP3A, CYP3A3, CYPIIIA3, CYPIIIA4, HLP, NF-25, P450C3, P450PCN1, cytochrome P450 family 3 subfamily A member 4, VDDR3
External IDsOMIM: 124010; HomoloGene: 111391; GeneCards: CYP3A4; OMA:CYP3A4 - orthologs
EC number1.14.13.32
Orthologs
SpeciesHumanMouse
Entrez

1576

n/a

Ensembl

ENSG00000160868

n/a

UniProt

P08684

n/a

RefSeq (mRNA)

NM_001202855
NM_001202856
NM_001202857
NM_017460

n/a

RefSeq (protein)

NP_001189784
NP_059488

n/a

Location (UCSC)Chr 7: 99.76 – 99.78 Mbn/a
PubMed search[2]n/a
Wikidata
View/Edit Human

Cytochrome P450 3A4 (abbreviated CYP3A4) (EC 1.14.13.97) is an important enzyme in the body, mainly found in the liver and in the intestine, which in humans is encoded by CYP3A4 gene. It oxidizes small foreign organic molecules (xenobiotics), such as toxins or drugs, so that they can be removed from the body. It is highly homologous to CYP3A5, another important CYP3A enzyme.

While many drugs are deactivated by CYP3A4, there are also some drugs that are activated by the enzyme. Some substances, such as some drugs and furanocoumarins present in grapefruit juice, interfere with the action of CYP3A4. These substances will, therefore, either amplify or weaken the action of those drugs that are modified by CYP3A4.

CYP3A4 is a member of the cytochrome P450 family of oxidizing enzymes. Several other members of this family are also involved in drug metabolism, but CYP3A4 is the most common and the most versatile one. Like all members of this family, it is a hemoprotein, i.e. a protein containing a heme group with an iron atom. In humans, the CYP3A4 protein is encoded by the CYP3A4 gene.[3] This gene is part of a cluster of cytochrome P450 genes on chromosome 7q22.1.[4] Previously another CYP3A gene, CYP3A3, was thought to exist; however, it is now thought that this sequence represents a transcript variant of CYP3A4. Alternatively-spliced transcript variants encoding different isoforms have been identified.[5]

Function

[edit]

CYP3A4 is a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases that catalyze many reactions involved in drug metabolism and synthesis of steroids (including cholesterol), and other lipids.[5]

The CYP3A4 protein localizes to the endoplasmic reticulum, and its expression is induced by glucocorticoids and some pharmacological agents.[5] Cytochrome P450 enzymes metabolize approximately 60% of prescribed drugs, with CYP3A4 responsible for about half of this metabolism;[6] substrates include acetaminophen (paracetamol), codeine, ciclosporin (cyclosporin), diazepam, erythromycin, and chloroquine.[5] The enzyme also metabolizes some steroids and carcinogens.[7] Most drugs undergo deactivation by CYP3A4, either directly or by facilitated excretion from the body. Also, many substances are bioactivated by CYP3A4 to form their active compounds, and many protoxins are toxicated into their toxic forms (see table below for examples).

CYP3A4 also possesses epoxygenase activity in that it metabolizes arachidonic acid to epoxyeicosatrienoic acids (EETs), i.e. (±)-8,9-, (±)-11,12-, and (±)-14,15-epoxyeicosatrienoic acids.[8] EETs have a wide range of activities including the promotion of certain types of cancers (see epoxyeicosatetraenoic acid). CYP3A4 promotes the growth of various types of human cancer cell lines in culture by producing (±)-14,15-epoxyeicosatrienoic acids, which stimulate these cells to grow.[9] The CYP3A4 enzyme is also reported to have fatty acid monooxgenase activity for metabolizing arachidonic acid to 20-Hydroxyeicosatetraenoic acid (20-HETE).[10] 20-HETE has a wide range of activities that include growth stimulation in breast and other types of cancers (see 12-hydroxyeicosatetraenoic acid).

Evolution

[edit]

The CYP3A4 gene exhibits a much more complicated upstream regulatory region in comparison with its paralogs.[11] This increased complexity renders the CYP3A4 gene more sensitive to endogenous and exogenous PXR and CAR ligands, instead of relying on gene variants for wider specificity.[11] Chimpanzee and human CYP3A4 are highly conserved in metabolism of many ligands, although four amino acids positively selected in humans led to a 5-fold benzylation of 7-BFC in the presence of the hepatotoxic secondary bile acid lithocholic acid.[12] This change in consequence contributes to an increased human defense against cholestasis.[12]

Tissue distribution

[edit]

Fetuses do not express CYP3A4 in their liver tissue, but rather CYP3A7 (EC 1.14.14.1), which acts on a similar range of substrates. CYP3A4 increases to approximately 40% of adult levels in the fourth month of life and 72% at 12 months.[13][14]

Although CYP3A4 is predominantly found in the liver, it is also present in other organs and tissues of the body, where it may play an important role in metabolism. CP3A4 is the major CYP enzyme in the intestine.[15] CYP3A4 in the intestine plays an important role in the metabolism of certain drugs. Often this allows prodrugs to be activated and absorbed, as in the case of the histamine H1-receptor antagonist terfenadine.

Recently CYP3A4 has also been identified in the brain, but its role in the central nervous system is still unknown.[16]

Mechanisms

[edit]

Cytochrome P450 enzymes perform an assortment of modifications on a variety of ligands, utilizing its large active site and its ability to bind more than one substrate at a time to perform complicated chemical alterations in the metabolism of endogenous and exogenous compounds. These include hydroxylation, epoxidation of olefins, aromatic oxidation, heteroatom oxidations, N- and O- dealkylation reactions, aldehyde oxidations, dehydrogenation reactions, and aromatase activity.[17][18]

Hydroxylation of an sp3 C-H bond is one of the ways in which CYP3A4 (and cytochrome P450 oxygenases) affects its ligand.[19] In fact, hydroxylation is sometimes followed by dehydrogenation, leading to more complex metabolites.[18] An example of a molecule that undergoes more than one reaction due to CYP3A4 includes tamoxifen, which is hydroxylated to 4-hydroxy-tamoxifen and then dehydrated to 4-hydroxy-tamoxifen quinone methide.[18]

Two mechanisms have been proposed as the primary pathway of hydroxylation in P450 enzymes.

Two of the most commonly proposed mechanisms used for the hydroxylation of an sp3 C–H bond

The first pathway suggested is a cage-controlled radical method ("oxygen rebound"), and the second involves a concerted mechanism that does not utilize a radical intermediate but instead acts very quickly via a "radical clock".[19]

Inhibition through fruit ingestion

[edit]

In 1998, various researchers showed that grapefruit juice, and grapefruit in general, is a potent inhibitor of CYP3A4, which can affect the metabolism of a variety of drugs, increasing their bioavailability.[20][21][22][23][24] In some cases, this can lead to a fatal interaction with drugs like astemizole or terfenadine.[21] The effect of grapefruit juice with regard to drug absorption was originally discovered in 1989. The first published report on grapefruit drug interactions was in 1991 in the Lancet entitled "Interactions of Citrus Juices with Felodipine and Nifedipine", and was the first reported food-drug interaction clinically. The effects of grapefruit last from 3–7 days, with the greatest effects when juice is taken an hour previous to administration of the drug.[25]

In addition to grapefruit, other fruits have similar effects. Noni (Morinda citrifolia), for example, is a dietary supplement typically consumed as a juice and also inhibits CYP3A4.[26] Pomegranate juice has shown some inhibition in limited studies, but has not yet demonstrated the effect in humans.[27][28]

Variability

[edit]

While over 28 single nucleotide polymorphisms (SNPs) have been identified in the CYP3A4 gene, it has been found that this does not translate into significant interindividual variability in vivo. It can be supposed that this may be due to the induction of CYP3A4 on exposure to substrates.

CYP3A4 alleles that have been reported to have minimal function compared to wild-type include CYP3A4*6 (an A17776 insertion) and CYP3A4*17 (F189S). Both of these SNPs led to decreased catalytic activity with certain ligands, including testosterone and nifedipine in comparison to wild-type metabolism.[29] By contrast, CYP3A4*1G allele has more potent enzymatic activity compared to CYP3A4*1A (the wild-type allele).[30]

Variability in CYP3A4 function can be determined noninvasively by the erythromycin breath test (ERMBT). The ERMBT estimates in vivo CYP3A4 activity by measuring the radiolabelled carbon dioxide exhaled after an intravenous dose of (14C-N-methyl)-erythromycin.[31]

Induction

[edit]

CYP3A4 is induced by a wide variety of ligands. These ligands bind to the pregnane X receptor (PXR). The activated PXR complex forms a heterodimer with the retinoid X receptor (RXR), which binds to the XREM region of the CYP3A4 gene. XREM is a regulatory region of the CYP3A4 gene, and binding causes a cooperative interaction with proximal promoter regions of the gene, resulting in increased transcription and expression of CYP3A4. Activation of the PXR/RXR heterodimer initiates transcription of the CYP3A4 promoter region and gene. Ligand binding increases when in the presence of CYP3A4 ligands, such as in the presence of aflatoxin B1, M1, and G1. Indeed, due to the enzyme's large and malleable active site, it is possible for the enzyme to bind multiple ligands at once, leading to potentially detrimental side effects.[32]

Induction of CYP3A4 has been shown to vary in humans depending on sex. Evidence shows an increased drug clearance by CYP3A4 in women, even when accounting for differences in body weight. A study by Wolbold et al. (2003) found that the median CYP3A4 levels measured from surgically removed liver samples of a random sample of women exceeded CYP3A4 levels in the livers of men by 129%. CYP3A4 mRNA transcripts were found in similar proportions, suggesting a pre-translational mechanism for the up-regulation of CYP3A4 in women. The exact cause of this elevated level of enzyme in women is still under speculation, however studies have elucidated other mechanisms (such as CYP3A5 or CYP3A7 compensation for lowered levels of CYP3A4) that affect drug clearance in both men and women.[33]

CYP3A4 substrate activation varies amongst different animal species. Certain ligands activate human PXR, which promotes CYP3A4 transcription, while showing no activation in other species. For instance, mouse PXR is not activated by rifampicin and human PXR is not activated by pregnenolone 16α-carbonitrile[34] In order to facilitate study of CYP3A4 functional pathways in vivo, mouse strains have been developed using transgenes in order to produce null/human CYP3A4 and PXR crosses. Although humanized hCYP3A4 mice successfully expressed the enzyme in their intestinal tract, low levels of hCYP3A4 were found in the liver.[34] This effect has been attributed to CYP3A4 regulation by the growth hormone signal transduction pathway.[34] In addition to providing an in vivo model, humanized CYP3A4 mice (hCYP3A4) have been used to further emphasize gender differences in CYP3A4 activity.[34]

CYP3A4 activity levels have also been linked to diet and environmental factors, such as duration of exposure to xenobiotic substances.[35] Due to the enzyme's extensive presence in the intestinal mucosa, the enzyme has shown sensitivity to starvation symptoms and is upregulated in defense of adverse effects. Indeed, in fatheaded minnows, unfed female fish were shown to have increased PXR and CYP3A4 expression, and displayed a more pronounced response to xenobiotic factors after exposure after several days of starvation.[35] By studying animal models and keeping in mind the innate differences in CYP3A4 activation, investigators can better predict drug metabolism and side effects in human CYP3A4 pathways.

Turnover

[edit]

Estimates of the turnover rate of human CYP3A4 vary widely. For hepatic CYP3A4, in vivo methods yield estimates of the enzyme half-life mainly in the range of 70 to 140 hours, whereas in vitro methods give estimates from 26 to 79 hours.[36] Turnover of gut CYP3A4 is likely to be a function of the rate of enterocyte renewal; an indirect approach based on the recovery of activity following exposure to grapefruit juice yields measurements in the 12- to 33-hour range.[36]

Technology

[edit]

Due to membrane-bound CYP3A4's natural propensity to conglomerate, it has historically been difficult to study drug binding in both solution and on surfaces. Co-crystallization is difficult since the substrates tend to have a low KD (between 5–150 μM) and low solubility in aqueous solutions.[37] A successful strategy in isolating the bound enzyme is the functional stabilization of monomeric CYP3A4 on silver nanoparticles produced from nanosphere lithography and analyzed via localized surface plasmon resonance spectroscopy (LSPR).[38] These analyses can be used as a high-sensitivity assay of drug binding, and may become integral in further high-throughput assays utilized in initial drug discovery testing. In addition to LSPR, CYP3A4-Nanodisc complexes have been found helpful in other applications including solid-state NMR, redox potentiometry, and steady-state enzyme kinetics.[38]

Ligands

[edit]

Following are lists of selected substrates, inducers and inhibitors of CYP3A4. Where classes of agents are listed, there may be exceptions within the class.

Substrates

[edit]

The substrates of CYP3A4 are:

Inhibitors

[edit]

Inhibitors of CYP3A4 are classified by potency:

  • a Strong inhibitor causes at least a 5-fold increase in the plasma AUC values, or more than 80% decrease in clearance.[39]
  • a Moderate inhibitor causes at least a 2-fold increase in the plasma AUC values, or 50–80% decrease in clearance.[39]
  • a Weak inhibitor causes at least a 1.25-fold but less than 2-fold increase in the plasma AUC values, or 20–50% decrease in clearance.[39]

The inhibitors of CYP3A4 are the following substances.

Strong inhibitors

[edit]

Moderate inhibitors

[edit]

Weak inhibitors

[edit]

Inhibitors of unspecified potency

[edit]

Inducers

[edit]

Strong and moderate CYP3A4 inducers are drugs that decrease the AUC of sensitive substrates of a given pathway where CYP3A4 is involved by ≥80 percent and ≥50 to <80 percent, respectively.[83][123] Weak inducers decrease the AUC by ≥20 to <50 percent.[123]

The inducers of CYP3A4 are the following substances.

Strong inducers

[edit]

Weak inducers

[edit]

Inducers of unspecified potency

[edit]

Interactive pathway map

[edit]

Click on genes, proteins and metabolites below to link to respective articles. [§ 1]

[[File:
IrinotecanPathway_WP46359go to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to article
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
[[
]]
IrinotecanPathway_WP46359go to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to articlego to article
|alt=Irinotecan Pathway edit]]
Irinotecan Pathway edit
  1. ^ The interactive pathway map can be edited at WikiPathways: "IrinotecanPathway_WP229".

See also

[edit]

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000160868 – Ensembl, May 2017
  2. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  3. ^ Hashimoto H, Toide K, Kitamura R, Fujita M, Tagawa S, Itoh S, Kamataki T (December 1993). "Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control". European Journal of Biochemistry. 218 (2): 585–95. doi:10.1111/j.1432-1033.1993.tb18412.x. PMID 8269949.
  4. ^ Inoue K, Inazawa J, Nakagawa H, Shimada T, Yamazaki H, Guengerich FP, Abe T (June 1992). "Assignment of the human cytochrome P-450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by fluorescence in situ hybridization". The Japanese Journal of Human Genetics. 37 (2): 133–8. doi:10.1007/BF01899734. PMID 1391968.
  5. ^ a b c d Public Domain This article incorporates public domain material from "CYP3A4 cytochrome P450 family 3 subfamily A member 4 [ Homo sapiens (human) ]". Reference Sequence collection. National Center for Biotechnology Information.
  6. ^ Zanger UM, Schwab M (April 2013). "Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation". Pharmacology & Therapeutics. 138 (1): 103–41. doi:10.1016/j.pharmthera.2012.12.007. PMID 23333322.
  7. ^ EntrezGene 1576
  8. ^ Bishop-Bailey D, Thomson S, Askari A, Faulkner A, Wheeler-Jones C (2014). "Lipid-metabolizing CYPs in the regulation and dysregulation of metabolism" (PDF). Annual Review of Nutrition. 34: 261–79. doi:10.1146/annurev-nutr-071813-105747. PMID 24819323. Archived (PDF) from the original on 18 January 2024. Retrieved 2 February 2024.
  9. ^ Fleming I (October 2014). "The pharmacology of the cytochrome P450 epoxygenase/soluble epoxide hydrolase axis in the vasculature and cardiovascular disease". Pharmacological Reviews. 66 (4): 1106–40. doi:10.1124/pr.113.007781. PMID 25244930.
  10. ^ Miyata N, Taniguchi K, Seki T, Ishimoto T, Sato-Watanabe M, Yasuda Y, Doi M, Kametani S, Tomishima Y, Ueki T, Sato M, Kameo K (June 2001). "HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme". British Journal of Pharmacology. 133 (3): 325–9. doi:10.1038/sj.bjp.0704101. PMC 1572803. PMID 11375247.
  11. ^ a b Qiu H, Mathäs M, Nestler S, Bengel C, Nem D, Gödtel-Armbrust U, Lang T, Taudien S, Burk O, Wojnowski L (March 2010). "The unique complexity of the CYP3A4 upstream region suggests a nongenetic explanation of its expression variability". Pharmacogenetics and Genomics. 20 (3): 167–78. doi:10.1097/FPC.0b013e328336bbeb. PMID 20147837. S2CID 205602787.
  12. ^ a b Kumar S, Qiu H, Oezguen N, Herlyn H, Halpert JR, Wojnowski L (June 2009). "Ligand diversity of human and chimpanzee CYP3A4: activation of human CYP3A4 by lithocholic acid results from positive selection". Drug Metabolism and Disposition. 37 (6): 1328–33. doi:10.1124/dmd.108.024372. PMC 2683693. PMID 19299527.
  13. ^ Johnson TN, Rostami-Hodjegan A, Tucker GT (2006). "Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children". Clinical Pharmacokinetics. 45 (9): 931–56. doi:10.2165/00003088-200645090-00005. PMID 16928154. S2CID 25596506.
  14. ^ Johnson TN, Tucker GT, Rostami-Hodjegan A (May 2008). "Development of CYP2D6 and CYP3A4 in the first year of life". Clinical Pharmacology and Therapeutics. 83 (5): 670–1. doi:10.1038/sj.clpt.6100327. PMID 18043691. S2CID 9714442.
  15. ^ Seden K, Dickinson L, Khoo S, David D (2010). "Grapefruit-drug interactions". Drugs. 70 (18): 2373–2407. doi:10.2165/11585250-000000000-00000. PMID 21142260.
  16. ^ Robertson GR, Field J, Goodwin B, Bierach S, Tran M, Lehnert A, Liddle C (July 2003). "Transgenic mouse models of human CYP3A4 gene regulation". Molecular Pharmacology. 64 (1): 42–50. doi:10.1124/mol.64.1.42. PMID 12815159. S2CID 17209434.
  17. ^ Schmiedlin-Ren P, Edwards DJ, Fitzsimmons ME, He K, Lown KS, Woster PM, Rahman A, Thummel KE, Fisher JM, Hollenberg PF, Watkins PB (November 1997). "Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins". Drug Metabolism and Disposition. 25 (11): 1228–33. PMID 9351897.
  18. ^ a b c Shahrokh K, Cheatham TE, Yost GS (October 2012). "Conformational dynamics of CYP3A4 demonstrate the important role of Arg212 coupled with the opening of ingress, egress and solvent channels to dehydrogenation of 4-hydroxy-tamoxifen". Biochimica et Biophysica Acta (BBA) - General Subjects. 1820 (10): 1605–17. doi:10.1016/j.bbagen.2012.05.011. PMC 3404218. PMID 22677141.
  19. ^ a b Meunier B, de Visser SP, Shaik S (September 2004). "Mechanism of oxidation reactions catalyzed by cytochrome p450 enzymes". Chemical Reviews. 104 (9): 3947–80. doi:10.1021/cr020443g. PMID 15352783. S2CID 33927145.
  20. ^ He K, Iyer KR, Hayes RN, Sinz MW, Woolf TF, Hollenberg PF (April 1998). "Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice". Chemical Research in Toxicology. 11 (4): 252–9. doi:10.1021/tx970192k. PMID 9548795.
  21. ^ a b Bailey DG, Malcolm J, Arnold O, Spence JD (August 1998). "Grapefruit juice-drug interactions". British Journal of Clinical Pharmacology. 46 (2): 101–10. doi:10.1046/j.1365-2125.1998.00764.x. PMC 1873672. PMID 9723817.
  22. ^ Garg SK, Kumar N, Bhargava VK, Prabhakar SK (September 1998). "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy". Clinical Pharmacology and Therapeutics. 64 (3): 286–8. doi:10.1016/S0009-9236(98)90177-1. PMID 9757152. S2CID 27490726.
  23. ^ Bailey DG, Dresser GK (2004). "Interactions between grapefruit juice and cardiovascular drugs". American Journal of Cardiovascular Drugs. 4 (5): 281–97. doi:10.2165/00129784-200404050-00002. PMID 15449971. S2CID 11525439.
  24. ^ Bressler R (November 2006). "Grapefruit juice and drug interactions. Exploring mechanisms of this interaction and potential toxicity for certain drugs". Geriatrics. 61 (11): 12–8. PMID 17112309.
  25. ^ Lilja JJ, Kivistö KT, Neuvonen PJ (October 2000). "Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin". Clinical Pharmacology and Therapeutics. 68 (4): 384–90. doi:10.1067/mcp.2000.110216. PMID 11061578. S2CID 29029956.
  26. ^ "Integrative Medicine, Noni". Memorial Sloan-Kettering Cancer Center. Archived from the original on 20 August 2013. Retrieved 27 June 2013.
  27. ^ Hidaka M, Okumura M, Fujita K, Ogikubo T, Yamasaki K, Iwakiri T, Setoguchi N, Arimori K (May 2005). "Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats". Drug Metabolism and Disposition. 33 (5): 644–8. doi:10.1124/dmd.104.002824. PMID 15673597. S2CID 7997718.
  28. ^ Anlamlert W, Sermsappasuk P (2020). "Pomegranate Juice does not Affect the Bioavailability of Cyclosporine in Healthy Thai Volunteers". Curr Clin Pharmacol. 15 (2): 145–151. doi:10.2174/1574884715666200110153125. PMC 7579232. PMID 31924158.
  29. ^ Lee SJ, Goldstein JA (June 2005). "Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests". Pharmacogenomics. 6 (4): 357–71. doi:10.1517/14622416.6.4.357. PMID 16004554. Archived from the original on 29 July 2020. Retrieved 25 May 2020.
  30. ^ a b Alkattan A, Alsalameen E. Polymorphisms of genes related to phase-I metabolic enzymes affecting the clinical efficacy and safety of clopidogrel treatment. Expert Opin Drug Metab Toxicol. 2021 Apr 30. doi: 10.1080/17425255.2021.1925249. Epub ahead of print. PMID 33931001.
  31. ^ Watkins PB (August 1994). "Noninvasive tests of CYP3A enzymes". Pharmacogenetics. 4 (4): 171–84. doi:10.1097/00008571-199408000-00001. PMID 7987401.
  32. ^ Ratajewski M, Walczak-Drzewiecka A, Sałkowska A, Dastych J (August 2011). "Aflatoxins upregulate CYP3A4 mRNA expression in a process that involves the PXR transcription factor". Toxicology Letters. 205 (2): 146–53. doi:10.1016/j.toxlet.2011.05.1034. PMID 21641981.
  33. ^ Wolbold R, Klein K, Burk O, Nüssler AK, Neuhaus P, Eichelbaum M, Schwab M, Zanger UM (October 2003). "Sex is a major determinant of CYP3A4 expression in human liver". Hepatology. 38 (4): 978–88. doi:10.1053/jhep.2003.50393. PMID 14512885.
  34. ^ a b c d Gonzalez FJ (2007). "CYP3A4 and pregnane X receptor humanized mice". Journal of Biochemical and Molecular Toxicology. 21 (4): 158–62. doi:10.1002/jbt.20173. PMID 17936928. S2CID 21501739. Archived from the original on 29 July 2020. Retrieved 6 September 2019.
  35. ^ a b Crago J, Klaper RD (September 2011). "Influence of gender, feeding regimen, and exposure duration on gene expression associated with xenobiotic metabolism in fathead minnows (Pimephales promelas)". Comparative Biochemistry and Physiology. Toxicology & Pharmacology. 154 (3): 208–12. doi:10.1016/j.cbpc.2011.05.016. PMID 21664292.
  36. ^ a b Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A (June 2008). "Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions". Current Drug Metabolism. 9 (5): 384–94. doi:10.2174/138920008784746382. PMID 18537575.
  37. ^ Sevrioukova IF, Poulos TL (January 2012). "Structural and mechanistic insights into the interaction of cytochrome P4503A4 with bromoergocryptine, a type I ligand". The Journal of Biological Chemistry. 287 (5): 3510–7. doi:10.1074/jbc.M111.317081. PMC 3271004. PMID 22157006.
  38. ^ a b Das A, Zhao J, Schatz GC, Sligar SG, Van Duyne RP (May 2009). "Screening of type I and II drug binding to human cytochrome P450-3A4 in nanodiscs by localized surface plasmon resonance spectroscopy". Analytical Chemistry. 81 (10): 3754–9. doi:10.1021/ac802612z. PMC 4757437. PMID 19364136.
  39. ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am an ao ap aq ar as at au av aw ax ay az ba bb bc bd be bf bg bh bi bj bk bl bm bn bo bp bq br bs bt bu bv bw bx by bz ca cb cc cd ce cf cg ch ci cj ck cl cm cn co cp cq cr cs ct cu cv cw cx cy cz da db dc dd de df dg dh di dj dk dl dm dn Flockhart DA (2007). "Drug Interactions: Cytochrome P450 Drug Interaction Table". Indiana University School of Medicine. Archived from the original on 10 October 2007. Retrieved 25 December 2008. Retrieved on 25 December 2008.
  40. ^ a b c d e f g h i j k l m n o p q r s t u v w x y z aa ab ac ad ae af ag ah ai aj ak al am an ao ap aq ar as at au av aw ax ay az ba bb bc bd be bf bg bh bi bj bk bl bm bn FASS (drug formulary): Swedish environmental classification of pharmaceuticals Archived 11 June 2002 at the Wayback Machine Facts for prescribers (Fakta för förskrivare). Retrieved July 2011
  41. ^ a b "Rinvoq: EPAR – Public assessment report Archived 21 July 2020 at the Wayback Machine" (PDF). European Medicines Agency. 5 March 2020. Archived (PDF) from the original on 21 July 2020. Retrieved 21 July 2020.
  42. ^ a b Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. 2020. Rinvoq 15 mg Retardtabletten.
  43. ^ "Erlotinib". Archived from the original on 24 December 2019. Retrieved 10 April 2018. Metabolized primarily by CYP3A4 and, to a lesser degree, by CYP1A2 and the extrahepatic isoform CYP1A1
  44. ^ "Cyclobenzaprine". DrugBank. Archived from the original on 27 October 2018. Retrieved 10 April 2018.
  45. ^ Azhar Y, Shaban K (2022). "Lurasidone". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 31082101. Archived from the original on 18 May 2023. Retrieved 14 October 2022.
  46. ^ Moody DE, Fang WB, Lin SN, Weyant DM, Strom SC, Omiecinski CJ (December 2009). "Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes". Drug Metabolism and Disposition. 37 (12): 2323–9. doi:10.1124/dmd.109.028605. PMC 2784702. PMID 19773542.
  47. ^ Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA (March 2004). "CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes". British Journal of Clinical Pharmacology. 57 (3): 287–97. doi:10.1046/j.1365-2125.2003.02002.x. PMC 1884456. PMID 14998425.
  48. ^ Tanaka E (October 1999). "Clinically significant pharmacokinetic drug interactions with benzodiazepines". Journal of Clinical Pharmacy and Therapeutics. 24 (5): 347–355. doi:10.1046/j.1365-2710.1999.00247.x. PMID 10583697. S2CID 22229823.
  49. ^ Sutton D, Butler AM, Nadin L, Murray M (July 1997). "Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites". The Journal of Pharmacology and Experimental Therapeutics. 282 (1): 294–300. PMID 9223567.
  50. ^ "Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers". U S Food and Drug Administration Home Page. 25 June 2009. Archived from the original on 23 April 2019. Retrieved 1 February 2019.
  51. ^ Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, Watkins PB (May 1997). "Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression". The Journal of Clinical Investigation. 99 (10). American Society for Clinical Investigation: 2545–53. doi:10.1172/jci119439. PMC 508096. PMID 9153299.
  52. ^ Bailey DG, Bend JR, Arnold JM, Tran LT, Spence JD (July 1996). "Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice". Clinical Pharmacology and Therapeutics. 60 (1). Springer Nature: 25–33. doi:10.1016/s0009-9236(96)90163-0. PMID 8689808. S2CID 1246705.
  53. ^ Guengerich FP, Brian WR, Iwasaki M, Sari MA, Bäärnhielm C, Berntsson P (June 1991). "Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4". Journal of Medicinal Chemistry. 34 (6): 1838–44. doi:10.1021/jm00110a012. PMID 2061924.
  54. ^ Katoh M, Nakajima M, Yamazaki H, Yokoi T (February 2001). "Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport". European Journal of Pharmaceutical Sciences. 12 (4): 505–13. doi:10.1016/s0928-0987(00)00215-3. PMID 11231118.
  55. ^ Foti RS, Rock DA, Wienkers LC, Wahlstrom JL (June 2010). "Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation". Drug Metabolism and Disposition. 38 (6). American Society for Pharmacology & Experimental Therapeutics (ASPET): 981–7. doi:10.1124/dmd.110.032094. PMID 20203109. S2CID 6823063.
  56. ^ Odou P, Ferrari N, Barthélémy C, Brique S, Lhermitte M, Vincent A, Libersa C, Robert H (April 2005). "Grapefruit juice-nifedipine interaction: possible involvement of several mechanisms". Journal of Clinical Pharmacy and Therapeutics. 30 (2): 153–8. doi:10.1111/j.1365-2710.2004.00618.x. PMID 15811168. S2CID 30463290.
  57. ^ "NIFEDIPINE EXTENDED RELEASE- nifedipine tablet, extended release". DailyMed. 29 November 2012. Archived from the original on 31 January 2022. Retrieved 1 February 2019. Drug Interactions: Nifedipine is mainly eliminated by metabolism and is a substrate of CYP3A. Inhibitors and inducers of CYP3A can impact the exposure to nifedipine and, consequently, its desirable and undesirable effects. In vitro and in vivo data indicate that nifedipine can inhibit the metabolism of drugs that are substrates of CYP3A, thereby increasing the exposure to other drugs. Nifedipine is a vasodilator, and coadministration of other drugs affecting blood pressure may result in pharmacodynamic interactions.
  58. ^ Zhang Y, Guo X, Lin ET, Benet LZ (April 1998). "Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor". Drug Metabolism and Disposition. 26 (4): 360–6. PMID 9531525.
  59. ^ Stringer KA, Mallet J, Clarke M, Lindenfeld JA (1992). "The effect of three different oral doses of verapamil on the disposition of theophylline". European Journal of Clinical Pharmacology. 43 (1): 35–8. doi:10.1007/bf02280751. PMID 1505606. S2CID 8942097.
  60. ^ Nielsen-Kudsk JE, Buhl JS, Johannessen AC (February 1990). "Verapamil-induced inhibition of theophylline elimination in healthy humans". Pharmacology & Toxicology. 66 (2): 101–3. doi:10.1111/j.1600-0773.1990.tb00713.x. PMID 2315261.
  61. ^ Gin AS, Stringer KA, Welage LS, Wilton JH, Matthews GE (August 1989). "The effect of verapamil on the pharmacokinetic disposition of theophylline in cigarette smokers". Journal of Clinical Pharmacology. 29 (8): 728–32. doi:10.1002/j.1552-4604.1989.tb03407.x. PMID 2778093. S2CID 20446675.
  62. ^ Sirmans SM, Pieper JA, Lalonde RL, Smith DG, Self TH (July 1988). "Effect of calcium channel blockers on theophylline disposition". Clinical Pharmacology and Therapeutics. 44 (1): 29–34. doi:10.1038/clpt.1988.108. PMID 3391002. S2CID 39570845.
  63. ^ Robson RA, Miners JO, Birkett DJ (March 1988). "Selective inhibitory effects of nifedipine and verapamil on oxidative metabolism: effects on theophylline". British Journal of Clinical Pharmacology. 25 (3): 397–400. doi:10.1111/j.1365-2125.1988.tb03319.x. PMC 1386365. PMID 3358901.
  64. ^ Abernethy DR, Egan JM, Dickinson TH, Carrum G (March 1988). "Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans". The Journal of Pharmacology and Experimental Therapeutics. 244 (3): 994–9. PMID 3252045.
  65. ^ a b Katoh M, Nakajima M, Yamazaki H, Yokoi T (October 2000). "Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4". Pharmaceutical Research. 17 (10): 1189–97. doi:10.1023/a:1007568811691. PMID 11145223. S2CID 24304693.
  66. ^ "Active ingredient: Tadalafil - Brands, Medical Use, Clinical Data". Druglib.com. Archived from the original on 28 November 2022. Retrieved 13 March 2022.
  67. ^ Cockshott ID (2004). "Bicalutamide: clinical pharmacokinetics and metabolism". Clinical Pharmacokinetics. 43 (13): 855–78. doi:10.2165/00003088-200443130-00003. PMID 15509184. S2CID 29912565.
  68. ^ a b Aquinos BM, García Arabehety J, Canteros TM, de Miguel V, Scibona P, Fainstein-Day P (2021). "[Adrenal crisis associated with modafinil use]". Medicina (in Spanish). 81 (5): 846–849. PMID 34633961.
  69. ^ Ledger T, Tong W, Rimmer J (August 2019). "Iatrogenic Cushing's syndrome with inhaled fluticasone". Australian Prescriber. 42 (4): 139–140. doi:10.18773/austprescr.2019.040. PMC 6698236. PMID 31427846.
  70. ^ El-Kommos ME, El-Gizawy SM, Atia NN, Hosny NM (2015). "Analysis for commonly prescribed non-sedating antihistamines". Analytical Chemistry Research. 3: 1–12. doi:10.1016/j.ancr.2014.11.003.
  71. ^ Jáuregui I, Mullol J, Bartra J, del Cuvillo A, Dávila I, Montoro J, Sastre J, Valero AL (2006). "H1 antihistamines: psychomotor performance and driving". J Investig Allergol Clin Immunol. 16 (Suppl 1): 37–44. PMID 17357376.
  72. ^ Li L, Liu R, Peng C, Chen X, Li J (July 2022). "Pharmacogenomics for the efficacy and side effects of antihistamines". Exp Dermatol. 31 (7): 993–1004. doi:10.1111/exd.14602. PMID 35538735.
  73. ^ Merk HF (November 2001). "Standard treatment: the role of antihistamines". J Investig Dermatol Symp Proc. 6 (2): 153–6. doi:10.1046/j.0022-202x.2001.00032.x. PMID 11764306.
  74. ^ Matsumoto S, Yamazoe Y (February 2001). "Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine". British Journal of Clinical Pharmacology. 51 (2): 133–42. doi:10.1111/j.1365-2125.2001.01292.x. PMC 2014443. PMID 11259984.
  75. ^ a b c d e Marzinke MA (1 January 2016). "Therapeutic Drug Monitoring of Antiretrovirals". In Clarke W, Dasgupta A (eds.). Chapter 6 - Therapeutic Drug Monitoring of Antiretrovirals. Clinical Challenges in Therapeutic Drug Monitoring. San Diego: Elsevier. pp. 135–163. doi:10.1016/B978-0-12-802025-8.00006-4. ISBN 978-0-12-802025-8. Archived from the original on 2 May 2024. Retrieved 6 February 2024.
  76. ^ Enzyme 1.14.13.32 Archived 27 March 2017 at the Wayback Machine at KEGG
  77. ^ "Showing Protein Cytochrome P450 3A4 (HMDBP01018)". Human Metabolome Database. Archived from the original on 2 May 2024. Retrieved 5 August 2017.
  78. ^ Daly AK, King BP (May 2003). "Pharmacogenetics of oral anticoagulants". Pharmacogenetics. 13 (5): 247–52. doi:10.1097/00008571-200305000-00002. PMID 12724615.
  79. ^ Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DG, Guyer KE, Bates ER (January 2003). "Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction". Circulation. 107 (1): 32–7. doi:10.1161/01.CIR.0000047060.60595.CC. PMID 12515739.
  80. ^ Meyer MR, Bach M, Welter J, Bovens M, Turcant A, Maurer HH (July 2013). "Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSn". Analytical and Bioanalytical Chemistry. 405 (19): 6307–21. doi:10.1007/s00216-013-7051-6. PMID 23774830. S2CID 27966043.
  81. ^ "LOSARTAN- losartan potassium tablet, film coated". DailyMed. 26 December 2018. Archived from the original on 7 February 2019. Retrieved 6 February 2019.
  82. ^ a b Taavitsainen P, Kiukaanniemi K, Pelkonen O (May 2000). "In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists". Eur J Clin Pharmacol. 56 (2): 135–40. doi:10.1007/s002280050731. PMID 10877007. S2CID 26865251.
  83. ^ a b c d e f g h i j k l m n "Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers". FDA. US Food and Drug Administration. 6 May 2023. Archived from the original on 4 November 2020. Retrieved 21 June 2020.
  84. ^ a b c d e f Flower R, Rang HP, Dale MM, Ritter JM (2007). Rang & Dale's pharmacology. Edinburgh: Churchill Livingstone. ISBN 978-0-443-06911-6.[page needed]
  85. ^ Kapetas AJ, Abuhelwa AY, Sorich MJ, McKinnon RA, Rodrigues AD, Rowland A, Hopkins AM (August 2021). "Evidence-Based Guidelines for Drug Interaction Studies: Model-Informed Time Course of Intestinal and Hepatic CYP3A4 Inhibition by Clarithromycin". AAPS J. 23 (5): 104. doi:10.1208/s12248-021-00632-7. PMID 34467456. S2CID 237373341.
  86. ^ Ushiama H, Echizen H, Nachi S, Ohnishi A (July 2002). "Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol". Clin Pharmacol Ther. 72 (1): 33–43. doi:10.1067/mcp.2002.125559. PMID 12152002.
  87. ^ Herdegen T, Cascorbi I (December 2023). "Drug Interactions of Tetrahydrocannabinol and Cannabidiol in Cannabinoid Drugs: Recommendations for Clinical Practice". Dtsch Arztebl Int. 120 (49): 833–840. doi:10.3238/arztebl.m2023.0223. PMC 10824494. PMID 37874128. S2CID 264438050.
  88. ^ a b c Hougaard Christensen MM, Bruun Haastrup M, Øhlenschlaeger T, Esbech P, Arnspang Pedersen S, Bach Dunvald AC, Bjerregaard Stage T, Pilsgaard Henriksen D, Thestrup Pedersen AJ (April 2020). "Interaction potential between clarithromycin and individual statins-A systematic review" (PDF). Basic Clin Pharmacol Toxicol. 126 (4): 307–317. doi:10.1111/bcpt.13343. PMID 31628882. Archived (PDF) from the original on 2 February 2024. Retrieved 2 February 2024. Erythromycin 500 mg three-four times daily for 6-7 days markedly increased lovastatin exposure (≈6-fold increase in AUC)
  89. ^ Park JY, Kim KA, Kim SL (November 2003). "Chloramphenicol is a potent inhibitor of cytochrome P450 isoforms CYP2C19 and CYP3A4 in human liver microsomes". Antimicrobial Agents and Chemotherapy. 47 (11): 3464–9. doi:10.1128/AAC.47.11.3464-3469.2003. PMC 253795. PMID 14576103.
  90. ^ a b c d e f g h i j k l m n o p q Center for Drug Evaluation and Research. "Drug Interactions & Labeling - Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers". www.fda.gov. Archived from the original on 23 April 2019. Retrieved 6 August 2018.
  91. ^ a b Darweesh RS, El-Elimat T, Zayed A, Khamis TN, Babaresh WM, Arafat T, Al Sharie AH (November 2020). "The effect of grape seed and green tea extracts on the pharmacokinetics of imatinib and its main metabolite, N-desmethyl imatinib, in rats". BMC Pharmacology & Toxicology. 21 (1): 77. doi:10.1186/s40360-020-00456-9. PMC 7670682. PMID 33198812.
  92. ^ a b Nishikawa M, Ariyoshi N, Kotani A, Ishii I, Nakamura H, Nakasa H, et al. (August 2004). "Effects of continuous ingestion of green tea or grape seed extracts on the pharmacokinetics of midazolam". Drug Metabolism and Pharmacokinetics. 19 (4): 280–289. doi:10.2133/dmpk.19.280. PMID 15499196.
  93. ^ a b Wanwimolruk S, Wong K, Wanwimolruk P (2009). "Variable inhibitory effect of different brands of commercial herbal supplements on human cytochrome P-450 CYP3A4". Drug Metabolism and Drug Interactions. 24 (1): 17–35. doi:10.1515/dmdi.2009.24.1.17. PMID 19353999. S2CID 27192663. Archived from the original on 21 October 2023. Retrieved 14 October 2023.
  94. ^ Francis Carballo-Arce A, Raina V, Liu S, Liu R, Jackiewicz V, Carranza D, et al. (June 2019). "Potent CYP3A4 Inhibitors Derived from Dillapiol and Sesamol". ACS Omega. 4 (6): 10915–10920. doi:10.1021/acsomega.9b00897. PMC 6648837. PMID 31460189.
  95. ^ Briguglio M, Hrelia S, Malaguti M, Serpe L, Canaparo R, Dell'Osso B, et al. (December 2018). "Food Bioactive Compounds and Their Interference in Drug Pharmacokinetic/Pharmacodynamic Profiles". Pharmaceutics. 10 (4): 277. doi:10.3390/pharmaceutics10040277. PMC 6321138. PMID 30558213.
  96. ^ Kondža M, Bojić M, Tomić I, Maleš Ž, Rezić V, Ćavar I (May 2021). "Characterization of the CYP3A4 Enzyme Inhibition Potential of Selected Flavonoids". Molecules. 26 (10): 3018. doi:10.3390/molecules26103018. PMC 8158701. PMID 34069400.
  97. ^ Kondža M, Mandić M, Ivančić I, Vladimir-Knežević S, Brizić I (January 2023). "Artemisia annua L. Extracts Irreversibly Inhibit the Activity of CYP2B6 and CYP3A4 Enzymes". Biomedicines. 11 (1): 232. doi:10.3390/biomedicines11010232. PMC 9855681. PMID 36672740.
  98. ^ Karakurt S (December 2016). "Modulatory effects of rutin on the expression of cytochrome P450s and antioxidant enzymes in human hepatoma cells". Acta Pharmaceutica. 66 (4): 491–502. doi:10.1515/acph-2016-0046. PMID 27749250. S2CID 20274417. Archived from the original on 18 June 2022. Retrieved 2 February 2024.
  99. ^ Ashour ML, Youssef FS, Gad HA, Wink M (2017). "Inhibition of Cytochrome P450 (CYP3A4) Activity by Extracts from 57 Plants Used in Traditional Chinese Medicine (TCM)". Pharmacognosy Magazine. 13 (50): 300–308. doi:10.4103/0973-1296.204561. PMC 5421430. PMID 28539725.
  100. ^ Product Information: ORAVIG(R) buccal tablets, miconazole buccal tablets. Praelia Pharmaceuticals, Inc (per FDA), Cary, NC, 2013.
  101. ^ Vetrichelvan O, Gorjala P, Goodman O, Mitra R (2021). "Bergamottin a CYP3A inhibitor found in grapefruit juice inhibits prostate cancer cell growth by downregulating androgen receptor signaling and promoting G0/G1 cell cycle block and apoptosis". PLOS ONE. 16 (9): e0257984. Bibcode:2021PLoSO..1657984V. doi:10.1371/journal.pone.0257984. PMC 8476002. PMID 34570813.
  102. ^ "Valerian: Health Benefits, Side Effects, Uses, Dose & Precautions". Archived from the original on 16 January 2018. Retrieved 10 April 2018.
  103. ^ Feng PF, Zhu LX, Jie J, Yang PX, Chen X (2021). "The Intracellular Mechanism of Berberine-Induced Inhibition of CYP3A4 Activity". Curr Pharm Des. 27 (40): 4179–4185. doi:10.2174/1381612827666210715155809. PMID 34269665. S2CID 235960940.
  104. ^ Nguyen JT, Tian DD, Tanna RS, Arian CM, Calamia JC, Rettie AE, Thummel KE, Paine MF (December 2023). "An Integrative Approach to Elucidate Mechanisms Underlying the Pharmacokinetic Goldenseal-Midazolam Interaction: Application of In Vitro Assays and Physiologically Based Pharmacokinetic Models to Understand Clinical Observations". J Pharmacol Exp Ther. 387 (3): 252–264. doi:10.1124/jpet.123.001681. PMC 10658920. PMID 37541764.
  105. ^ Hermann R, von Richter O (September 2012). "Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions". Planta Medica. 78 (13): 1458–77. doi:10.1055/s-0032-1315117. PMID 22855269.
  106. ^ Feng P, Zhao L, Guo F, Zhang B, Fang L, Zhan G, Xu X, Fang Q, Liang Z, Li B (September 2018). "The enhancement of cardiotoxicity that results from inhibiton of CYP 3A4 activity and hERG channel by berberine in combination with statins". Chemico-Biological Interactions. 293: 115–123. Bibcode:2018CBI...293..115F. doi:10.1016/j.cbi.2018.07.022. PMID 30086269. S2CID 206489481.
  107. ^ Zhang W, Ramamoorthy Y, Tyndale RF, Sellers EM (June 2003). "Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro". Drug Metabolism and Disposition. 31 (6): 768–72. doi:10.1124/dmd.31.6.768. PMID 12756210. S2CID 16229370.
  108. ^ Nabekura T, Yamaki T, Kitagawa S (2009). "Interaction of coffee diterpenes, cafestol and kahweol, with human P-glycoprotein" (PDF). AAPS Journal. The American Association of Pharmaceutical Scientists. Archived from the original (PDF) on 21 July 2011.
  109. ^ Kheoane PS, Enslin GM, Tarirai C (December 2021). "Determination of effective concentrations of drug absorption enhancers using in vitro and ex vivo models". Eur J Pharm Sci. 167: 106028. doi:10.1016/j.ejps.2021.106028. PMID 34601070. S2CID 238257296.
  110. ^ Wen X, Wang JS, Kivistö KT, Neuvonen PJ, Backman JT (2001). "In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9)". Br J Clin Pharmacol. 52 (5): 547–53. doi:10.1046/j.0306-5251.2001.01474.x. PMC 2014611. PMID 11736863.
  111. ^ Phucharoenrak P, Trachootham D (February 2024). "Bergaptol, a Major Furocoumarin in Citrus: Pharmacological Properties and Toxicity". Molecules. 29 (3): 713. doi:10.3390/molecules29030713. PMC 10856120. PMID 38338457.
  112. ^ Yamaori S, Ebisawa J, Okushima Y, Yamamoto I, Watanabe K (April 2011). "Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety". Life Sciences. 88 (15–16): 730–6. doi:10.1016/j.lfs.2011.02.017. PMID 21356216.
  113. ^ Kondža M, Brizić I, Jokić S (March 2024). "Flavonoids as CYP3A4 Inhibitors In Vitro". Biomedicines. 12 (3): 644. doi:10.3390/biomedicines12030644. PMC 10968035. PMID 38540257.
  114. ^ a b Non-nucleoside reverse-transcriptase inhibitors have been shown to both induce and inhibit CYP3A4.
  115. ^ Hidaka M, Fujita K, Ogikubo T, Yamasaki K, Iwakiri T, Okumura M, Kodama H, Arimori K (June 2004). "Potent inhibition by star fruit of human cytochrome P450 3A (CYP3A) activity". Drug Metabolism and Disposition. 32 (6): 581–3. doi:10.1124/dmd.32.6.581. PMID 15155547. S2CID 17392051.
  116. ^ "HCVadvocate.org". Archived from the original on 5 March 2010.
  117. ^ Gaudineau C, Auclair K (May 2004). "Inhibition of human P450 enzymes by nicotinic acid and nicotinamide". Biochemical and Biophysical Research Communications. 317 (3): 950–6. doi:10.1016/j.bbrc.2004.03.137. PMID 15081432.
  118. ^ Kimura Y, Ito H, Ohnishi R, Hatano T (January 2010). "Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity". Food and Chemical Toxicology. 48 (1): 429–35. doi:10.1016/j.fct.2009.10.041. PMID 19883715. Ginko Biloba has been shown to contain the potent inhibitor amentoflavone
  119. ^ Lim YP, Ma CY, Liu CL, Lin YH, Hu ML, Chen JJ, Hung DZ, Hsieh WT, Huang JD (2012). "Sesamin: A Naturally Occurring Lignan Inhibits CYP3A4 by Antagonizing the Pregnane X Receptor Activation". Evidence-Based Complementary and Alternative Medicine. 2012: 242810. doi:10.1155/2012/242810. PMC 3356939. PMID 22645625.
  120. ^ Bhardwaj RK, Glaeser H, Becquemont L, Klotz U, Gupta SK, Fromm MF (August 2002). "Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4". The Journal of Pharmacology and Experimental Therapeutics. 302 (2): 645–50. doi:10.1124/jpet.102.034728. PMID 12130727. S2CID 7398172.
  121. ^ Wen X, Wang JS, Neuvonen PJ, Backman JT (January 2002). "Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes". European Journal of Clinical Pharmacology. 57 (11): 799–804. doi:10.1007/s00228-001-0396-3. PMID 11868802. S2CID 19299097.
  122. ^ Ekstein D, Schachter SC (May 2010). "Natural Products in Epilepsy-the Present Situation and Perspectives for the Future". Pharmaceuticals. 3 (5): 1426–1445. doi:10.3390/ph3051426. PMC 4033990. PMID 27713311.
  123. ^ a b Molenaar-Kuijsten L, Van Balen DE, Beijnen JH, Steeghs N, Huitema AD (2021). "A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs". Front Pharmacol. 12: 670862. doi:10.3389/fphar.2021.670862. PMC 8435708. PMID 34526892.
  124. ^ Astellas Pharma US, Inc. (August 2012). "Highlights of Prescribing Information: XTANDI (enzalutamide) capsules for oral use" (PDF). U.S. Food and Drug Administration. Archived (PDF) from the original on 31 July 2018. Retrieved 10 April 2018.
  125. ^ Schelleman H (February 2015). "AExposure to CYP3A4 inducing and CYP3A4 non-inducing antiepileptic agents and the risk of fractures". Pharmacoepidemiol Drug Saf. 20 (6): 619–625. doi:10.1002/pds.2141. PMC 4340253. PMID 21538673.
  126. ^ Johannessen SI, Landmark CJ (September 2010). "Antiepileptic drug interactions - principles and clinical implications". Current Neuropharmacology. 8 (3): 254–67. doi:10.2174/157015910792246254. PMC 3001218. PMID 21358975.
  127. ^ Nallani SC, Glauser TA, Hariparsad N, Setchell K, Buckley DJ, Buckley AR, Desai PB (December 2003). "Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate". Epilepsia. 44 (12): 1521–8. doi:10.1111/j.0013-9580.2003.06203.x. PMID 14636322. S2CID 6915760.
  128. ^ Han EH, Kim HG, Choi JH, Jang YJ, Lee SS, Kwon KI, Kim E, Noh K, Jeong TC, Hwang YP, Chung YC, Kang W, Jeong HG (May 2012). "Capsaicin induces CYP3A4 expression via pregnane X receptor and CCAAT/enhancer-binding protein β activation". Molecular Nutrition & Food Research. 56 (5): 797–809. doi:10.1002/mnfr.201100697. PMID 22648626. S2CID 26584141.
[edit]

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

Retrieved from "https://en.wikipedia.org/w/index.php?title=CYP3A4&oldid=1234732622"